ADG126

DRUG5 trials

Conditions

Advanced Liver CancersAdvanced liver cancersAdvanced/Metastatic Solid TumorsLocally Advanced Colorectal CancerSolid Tumor

Phase 1

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

RecruitingNCT04524871

Hoffmann-La RocheAdvanced Liver Cancers

Start: 2020-11-01End: 2027-12-31Target: 518Updated: 2026-03-27

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

RecruitingNCT05405595

Adagene IncAdvanced/Metastatic Solid Tumors

Start: 2022-06-15End: 2027-04-30Target: 186Updated: 2026-01-07

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

RecruitingNCT05584670

SanofiSolid Tumor

Start: 2022-11-29End: 2028-06-28Target: 542Updated: 2026-01-20

A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH ADVANCED LIVER CANCERS (MORPHEUS LIVER)

Not yet recruitingCTIS2023-506611-17-00

F. Hoffmann-La Roche AGAdvanced liver cancers

Target: 29Updated: 2025-12-04

Phase 2

Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

RecruitingNCT06846268

National University Hospital, SingaporeLocally Advanced Colorectal Cancer

Start: 2025-04-14End: 2027-12-31Target: 20Updated: 2025-07-25

Journal of Clinical Oncology2025-05-281 citations

Initial safety and efficacy results from a first-in-human, phase 1/2 study of SAR445877, an anti-PD-1/IL-15 fusion protein, for patients with advanced solid tumors.

Journal of Clinical Oncology2025-05-28

Update of phase 1b/2 study of muzastotug (ADG126, an anti-CTLA-4 SAFEbody) in combination with pembrolizumab in advanced/metastatic MSS CRC.

Journal of Clinical Oncology2025-01-271 citations

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.

2025-01-2141 citations

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Cancer Research Communications2024-03-2914 citations

Results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody) in combo with pembrolizumab (Pembro) in patients (Pts) with metastatic microsatellite-stable (MSS) colorectal cancer (CRC).

Journal of Clinical Oncology2024-01-20

779 A phase 1/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors

Regular and Young Investigator Award Abstracts2023-10-312 citations

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

Journal for ImmunoTherapy of Cancer2023-06-0183 citations

Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).

Journal of Clinical Oncology2023-06-0149 citations

Abstract CT233: Initial results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody®) in combination with pembrolizumab (an anti-PD-1 antibody) in patients with advanced/metastatic solid tumors

Cancer Research2023-04-14

Abstract 2972: Preclinical characterization of SAR445877, an anti-PD-1 antibody-IL-15 mutein fusion protein with robust anti-tumor efficacy as monotherapy and in combination with PD-L1 blockade

Cancer Research2023-04-041 citations

ADG126

Sponsors

Conditions

Phase 1

Phase 2

Related Papers